Abstract Objectives: The aim of this study was to evaluate a possible correlation between plasma levels of interleukin-6 (IL-6), metalloproteinase-9 (MMP-9) and C-reactive protein (CRP) and the expansion of small abdominal aortic aneurysms (AAAs). Design: Patients were selected from a prospective randomised clinical trial and categorised in two groups, in which one group received active treatment (azithromycin) and the other received placebo. No statistical difference in the expansion rate of AAAs between the groups was found and the two groups were considered as one cohort in the present study. Material and methods: In this study, 213 patients with AAAs between 35 and 49 mm were followed-up with ultrasound examination every 6th month. Blood samples were taken on two occasions (6 months apart). IL-6 and MMP-9 were analysed on one occasion using Quantikine â analysing kits (R&D Systems, Inc., USA). CRP was analysed using sensitive-CRP method. Results: Levels of IL-6, MMP-9 and CRP did not correlate with AAA expansion. Neither was there any correlation between statin medication and changes in MMP-9 levels over the 6-month period. Patients on statins had a lower expansion rate than those not taking statins: 0.16 versus 0.25 cm per year. Conclusion: No correlation was found between levels of circulating IL-6, MMP-9, CRP and the expansion of small-diameter AAAs, indicating no clinical use of these markers in AAA surveillance. ª
Proteolytic degeneration of the aortic wall and chronic inflammation are considered important in the pathogenesis of abdominal aortic aneurysms (AAAs). 1, 2 Experimental studies of elastase-induced aneurysms indicate that an inflammatory reaction within the aortic media is crucial for aortic dilatation. 3 A human biopsy study has confirmed the association between the extent of inflammation of the aortic wall and aortic diameter. 4 Interleukin-6 (IL-6), metalloproteinase-9 (MMP-9) and C-reactive protein (CRP) are markers of inflammatory processes and have all been associated with AAA pathogenesis, while also being easy to analyse in peripheral blood samples. Presuming the importance of inflammation in AAA expansion, it is tempting to assume that there may be a correlation between plasma levels of these substances and expansion rate. IL-6 is one of the pro-inflammatory cytokines mediating MMP-9 expression and stimulation of CRP production. 5 Moreover, AAA may be an important source of circulating IL-6.
6 MMP-9 is associated with the expansion of AAA shown both in in vitro and in vivo studies, 4, 7, 8 and interestingly MMP-9 might be suppressed by statins.
9e11 CRP levels might be higher in patients with AAA as compared to patients with aortic occlusive disease. 12 It has also been suggested that there is an association between serum levels of CRP and AAA size. 13 This study aimed to evaluate the correlation (if any) between circulating levels of IL-6, MMP-9 and CRP and the expansion of small-diameter AAAs.
Materials and Methods
This study included 213 patients with an AAA diameter of 35e49 mm selected from a clinical trial conducted between May 2002 and August 2005. Of these patients, one group received active treatment (azithromycin) and the other received placebo. This study aimed to examine the effect of azithromycin on the expansion of small-diameter AAAs. Patients were recruited from the AAA surveillance programme. Exclusion criteria were: AAA <35 mm or AAA !50 mm, age >81 years, intolerance to macrolide antibiotics, creatinine clearance <40 ml min À1 and medication with ergotamine. As there was no statistical difference in the expansion rate of the AAAs between the groups, both groups are considered as a single cohort in the present study. Ultrasound examination was carried out in a standardised way every 6th month for a minimum of 18 months. The widest antero-posterior diameter was measured in both axial and transverse angles. Medical history, current medication and smoking habits were recorded. Blood samples were taken on two occasions e at inclusion and 6 months after joining the study. Plasma was stored at À70 C until analysis of IL-6, MMP-9 and CRP. Plasma samples for IL-6 (182 patients) and MMP-9 (196 patients) were analysed at a single occasion using Quantikine â analysing kits (R&D Systems, Inc, USA). Plasma samples from 198 patients were analysed for CRP using CRP â a-Tina-quant (Roche/ Hitachi, Germany). All samples were assayed in a single batch, and were run in duplicates.
Statistical Analysis
Categorical variables were summarised by percentages and counts and continuous variables by medians and interquartile ranges (IQR). For each patient with at least two measurements, the average expansion rate of the AAA diameter was estimated through a linear regression model. For IL-6, MMP-9 and CRP, an average change of the log level of the concentration was estimated in a similar way with a linear regression model for each patient. The number of patients with decreasing, unchanged or increasing levels were summarised. To compare the expansion rate of the AAA with the change in levels of the different markers, Spearman correlation coefficients were calculated from the individually estimated slopes. The WilcoxoneManneWhitney test was used for comparing expansion rates between groups. Confidence intervals were calculated using the percentile method on 10 000 bootstrap samples. All statistical analyses were done using R version 2.5.2.
14 Ethics All patients gave their written consent after being provided with complete information about the study. The study was approved by the Committee of Ethics of Uppsala University (Dno; 01-349).
Results
Every 6th month, 213 patients were followed-up by ultrasound examination. The median AAA diameter at inclusion was 4.0 cm (range: 3.7e4.4 cm). The median age was 71 years, and 76.5% of the subjects were men. As seen in Table  1 , this cohort is representative for patients with AAA. The low number (5.6%) of patients with chronic obstructive pulmonary disease (COPD) is probably because the diagnosis was confirmed only by oral confession. Most patients had atherosclerotic manifestations, of which 58.7% suffered hypertension and 85 patients (39.9%) were on medication with statins. The mean annual AAA expansion rate was 0.25 cm. Levels of IL-6 were unchanged in nine (4.9%), decreased in 83 (46%) and showed an increase in 90 (49%) patients. MMP-9 levels were unchanged in two (1%) patients, 112 (57%) showed a decrease and 82 (42%) an increase, and CRP levels were unchanged in three (1.5%) patients, while 106 (54%) showed a decease and 89 (45%) an increase over the 6-month period (Table 2) . No correlation was found between plasma levels of IL-6, MMP-9 and CRP and the expansion of small-diameter AAAs, irrespective of azithromycin treatment (Tables 2 and 3 ). The correlations for the 6 months studied between AAA expansion and the parameters were: IL-6 e r Z 0.08, p Z 0.31; MMP-9 e r Z 0.09, p Z 0.19 and CRP: r Z À0.03, p Z 0.70. There were no differences between patients on statin medication and those not on statin medication regarding changes in MMP-9 levels over the 6-month period studied. However, 85 patients on statin medication had a lower median expansion rate than 127 patients not taking statins (0.16 versus 0.25 cm per year, WilcoxoneManneWhitney p-value: 0.008, 95% bootstrap confidence interval for the difference: 0.003e0.15). Among non-smokers and smokers, 44% and 34% were on statins, respectively. No change in antiinflammatory medication was reported, although seven patients had ceased smoking after 18 months into the study.
Discussion
The present study examined the correlation between circulating levels of IL-6, MMP-9 and CRP, all markers of inflammation, and the expansion of small-diameter AAAs over a 6-month period. IL-6, MMP-9 and CRP have all been associated with AAA pathogenesis. Presuming the importance of inflammation in AAA expansion, it is tempting to suggest a correlation between plasma levels of these substances and the expansion rate. Circulating IL-6 has been detected in significantly higher concentrations in AAA patients, compared to patients with either coronary heart disease or healthy controls. 15 Patients detected with early aortic dilatation may have increased serum levels of IL-6, 16 indicating that inflammation might be of importance in early AAA formation. IL-6 is found in high concentrations in aneurysmal-wall biopsies, 5, 17 and AAAs seem to be a source of circulating IL-6. 6 However, Jones et al. 6 could not detect any association between IL-6 levels and the growth rate. Furthermore, IL-6 has a central role in the acute-phase response stimulating elevation of MMP-9 and CRP levels and in the activation of B and T lymphocytes. Over the years, a body of evidence has grown in favour of an association especially between MMP-9 e and AAA pathogenesis. MMP-9 can be analysed not only in tissue biopsies but also in peripheral blood samples. It has been proposed that MMP-9 may be a marker for inflammation. 18 Patients with AAA have higher levels of MMP-9 in peripheral blood samples than patients with aortic occlusive disease (AOD) and healthy volunteers, 19, 20 indicating that MMP-9 may serve as a marker for tissue metabolism in patients with AAA. Organ culture studies suggest that aneurysmal tissue is the source of MMP-9, 3,21,22 and interestingly Pyo et al. reported that MMP-9-deficient mice were aneurysm resistant, as opposed to MMP-12-deficient mice, indicating MMP-9 as a crucial enzyme in AAA formation. 8 A number of studies show an association between the expansion of AAAs and MMP-9 levels and indications that larger aneurysms have higher levels of MMP-9 as compared to smaller AAAs. 4, 7, 23, 24 It has been proposed that high MMP-9 activity in the AAA wall is associated with rupture. 25 There may be a difference in MMP-9 activity between males and females, with lower activity in females, supporting gender-related differences in AAA formation as demonstrated in an experimental AAA model. 26 The use of statins is increasing, and there are indications that statins may attenuate/suppress MMP-9 activity.
9e11 However, no such effect was detected in the present study. Interestingly, no statistical difference was detected in baseline MMP-9 levels between statin and nonstatin users, indicating that statin medications do not alter MMP-9 levels in plasma (data not shown). Others have used in vitro tissue analysis, whereas we have used peripheral blood which might explain the contradictory results. CRP has emerged as a risk factor for atherosclerosis and its progression. 27e29 Powell et al. 12 reported that serum CRP was elevated in patients operated on for AAA as compared to patients operated for AOD. Furthermore, patients with AAA have higher CRP levels in serum than controls without AAA, 30 although CRP may not be associated with rapid expansion. 31 There are studies where a significant elevation of CRP has been found in symptomatic, or even ruptured, AAAs as compared to asymptomatic AAAs. 32, 33 Moreover, CRP might be, in at least some patients, produced by aneurysmal and atherosclerotic tissue e that is, macrophages and smooth muscle cells, underscoring the inflammatory nature of AAA. 13, 34 The expansion pattern of AAAs has been estimated to be about 10% per annum. Although this is not applicable for the individual AAA patient, it is well known among clinicians that there are large individual variations in expansion patterns, with episodes of rapid expansion that may be followed by periods of slower, or even cessation of, expansion. It would be of interest to find a marker for identifying aneurysms with progressive growth that indicates a necessity for treatment. Markers of inflammatory processes could be of 106  54  3  2  89  45  Placebo  52  54  0  0  45  46  Azithromycin 54  54  3  3  44  44 interest, both from the expansion point of view and as targets for novel pharmacological therapy in minimising growth. Undoubtedly, patients with an AAA have higher levels of IL-6, MMP-9 and CRP than patients with either AOD, coronary heart disease or in healthy volunteers, indicating an on-going inflammatory process in patients with AAA. We could not, however, detect a correlation between levels of circulating IL-6, MMP-9, CRP and the expansion of smalldiameter AAAs, indicating several possibilities: the inflammation is persistent or low active, that is, no dramatic changes over time; the process might be 'cold' or secondary to e for instance, hypoxia e and might not release IL-6, MMP-9 or CRP into the circulation. The strength of this study is the relatively large sample size, although hampered by the retrospective nature of the study.
In conclusion, we state that there is no clinical use of these markers (IL-6, MM-9 and CRP) in AAA surveillance. Ultrasound examination remains the surveillance tool of choice. We could not establish a correlation between the use of statins and plasma levels of MMP-9. Patients on statins had a lower expansion rate than those not on statins. This finding warrants further studies.
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